InvestorsHub Logo
Followers 468
Posts 26931
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Friday, 05/02/2008 8:52:07 AM

Friday, May 02, 2008 8:52:07 AM

Post# of 96
Avalon Pharmaceuticals to Release First Quarter 2008 Results

Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the first quarter of 2008 on Wednesday, May 7, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, May 8, 2008 at 8:30 am Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet or by dialing the numbers listed below.

Conference Call details:
Dial-In: (877) 419-6597 (U.S.)
(719) 325-4858 (International)

Passcode: 4845885

Webcast:

To access the call by live webcast, please visit the Investor Relations section of our website at http://www.Avalonrx.com. An archived version of the webcast will be available for 30 days.

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon’s lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx® is the company’s proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.

Avalon Pharmaceuticals, Inc.
C. Eric Winzer
Executive Vice President &
Chief Financial Officer
301-556-9900
Fax: (301) 556-9910
info@avalonrx.com
or
Dorland Global Public Relations
Kate Gormley (Media)
215-928-2720
kgormley@dorland.com
or
The Trout Group
Chad Rubin (Investors)
646-378-2947


Source: Business Wire (April 30, 2008 - 8:01 AM EDT)

News by QuoteMedia
www.quotemedia.com
http://biz.yahoo.com/cc/9/93009.html


surf's up......crikey